DUBLIN–(BUSINESS WIRE)–The “Estrogen Receptor Beta – Pipeline Review, H2 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.
‘Estrogen Receptor Beta – Pipeline Review, H2 2020’; Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) pipeline Target constitutes close to 20 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes.
Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) – Estrogen receptor beta (ERB) is a nuclear receptor that is activated by the sex hormone estrogen. It is encoded by the gene ESR2. Upon binding to 17beta-estradiol or related ligands, the encoded protein forms homo- or hetero-dimers that interact with specific DNA sequences to activate transcription.
The report ‘Estrogen Receptor Beta – Pipeline Review, H2 2020’ outlays comprehensive information on the Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 1, 5, 3 and 5 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 2 and 2 molecules, respectively.
Scope
- The report provides a snapshot of the global therapeutic landscape for Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2)
- The report reviews Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics
Key Topics Covered:
Introduction
- Report Coverage
Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) – Overview
Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) – Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) – Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) – Companies Involved in Therapeutics Development
- AstraZeneca Plc
- Atossa Therapeutics Inc
- Avivia BV
- Eagle Pharmaceuticals Inc
- Eli Lilly and Co
- Endece LLC
- EndoCeutics Inc
- Helixmith Co Ltd
- Huons Co Ltd
- Karo Pharma AB
- Kissei Pharmaceutical Co Ltd
- MEI Pharma Inc
- Oasmia Pharmaceutical AB
Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) – Drug Profiles
(bazedoxifene acetate + cholecalciferol) – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- acolbifene + prasterone – Drug Profile
- AUS-131 – Drug Profile
- dehydrodiconiferyl alcohol – Drug Profile
- Drug to Agonize ER-Beta for Multiple Sclerosis – Drug Profile
- erteberel – Drug Profile
- estradiol – Drug Profile
- fosfestrol – Drug Profile
- fulvestrant – Drug Profile
- fulvestrant – Drug Profile
- fulvestrant – Drug Profile
- KB-3944 – Drug Profile
- KB-9520 – Drug Profile
- Libidua – Drug Profile
- Loseasonique – Drug Profile
- NDC-1308 – Drug Profile
- Small Molecule to Agonize ESR2 for Obesity and Depression – Drug Profile
- Small Molecule to Agonize ESR2 for Oncology – Drug Profile
- Small Molecules to Agonize ESR2 for Multiple Sclerosis – Drug Profile
- Small Molecules to Agonize Estrogen Beta Receptor for Inflammatory Diseases and Oncology – Drug Profile
- SR-16234 – Drug Profile
Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) – Dormant Products
Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) – Discontinued Products
Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) – Product Development Milestones
- Featured News & Press Releases
- May 04, 2020: Eagle Pharmaceuticals advances novel and proprietary formulation of Fulvestrant product candidate EA-114; company to request additional meeting with U.S. Food and Drug Administration
Appendix
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/fsjdyd
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900